Study bolsters hopes for prostate cancer vaccine rejected by FDA
Wednesday, April 29, 2009 - 02:14
in Health & Medicine
The vaccine, Provenge, extended life an average of four months, nearly twice as long as the best available chemotherapy, researchers say. A controversial prostate cancer vaccine that previously had been rejected by the Food and Drug Administration improves survival of patients with the advanced form of the disease more than existing treatments and should be brought to market, researchers said Tuesday.
Read the whole article on LA Times - Science
More from LA Times - Science
Related
- Therapeutic vaccine prolongs survival and improves quality of lifeThu, 15 May 2008, 9:29:13 EDT
- Prostate cancer vaccines more effective with hormone therapyThu, 10 Jul 2008, 0:28:34 EDT
- Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancerWed, 29 Apr 2009, 9:09:30 EDT
- Cancer vaccine shows promise in patients with bowel, kidney and prostate cancerThu, 23 Oct 2008, 18:36:26 EDT
- Vaccine shows therapeutic promise against advanced melanomaMon, 1 Jun 2009, 9:44:24 EDT